Our board combines deep experience in drug discovery, commercialisation and life sciences with decades of experience in finance and technology.

 

Ray brings the experience, knowledge and personal network from more than 20 highly productive years in regional and global leadership positions spanning the complete value chain in the Pharmaceutical and Biotechnology industries. Having completed his PhD at University of Manchester, UK in 1994 and a post-doctoral fellowship at McGill University in Canada, Ray joined the Technology Access and Strategic Alliances Team at Zeneca in 1995, becoming the Team Leader only a few years later. After the merger with Astra, Ray took a global management role, in-licensing new technologies and developing molecules in oncology, cardiovascular, respiratory and inflammatory disease areas, while concurrently obtaining an MBA (with distinction) at the Manchester Business School. He then moved into Business Development as a Senior Analyst and then Director of Corporate Development, where he spearheaded a number of transactions and contributed to shaping AstraZeneca’s strategic roadmap, including its entry into biologics.

Following a period leading regional commercial operations for AstraZeneca in 14 European countries and Russia, Ray moved to senior business development roles in the biotech sector, where he out-licensed a portfolio of Meningitis B assets to Sanofi, and was involved in successfully listing Emergent Solutions, Inc. (EBS) on NASDAQ. Ray also ran his own business (BD Solutions Limited) for five years, advising clients on corporate development and commercialisation, including as CEO of Asterion Limited, where he successfully closed deals with Genzyme Inc. and Ipsen. 

Ray joined Crucell NV in 2010 and was part of the team instrumental in its sale to Johnson & Johnson, for whom he orchestrated deals in infectious diseases and vaccines before becoming Executive Director of Corporate Development at Amgen in 2012. In this role, Ray closed immuno-oncology deals with Boehringer Ingelheim, negotiated international commercial deals with GSK, Mitsubishi Tanabe and Novartis, and played a key part in the acquisition of Onyx Pharmaceuticals Inc. and Dezima Pharma BV. Ray took up the role of Chief Executive Officer at e-therapeutics on 6 April 2017.